Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome
- 25 July 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 122 (4) , 554-561
Abstract
Some neonates with Down syndrome (DS) are diagnosed with self-regressing transient myeloproliferative disorder (TMD), and 20% to 30% of those progress to acute megakaryoblastic leukemia (AMKL). We performed exome sequencing in 7 TMD/AMKL cases and copy-number analysis in these and 10 additional cases. All TMD/AMKL samples contained GATA1 mutations. No exome-sequenced TMD/AMKL sample had other recurrently mutated genes. However, 2 of 5 TMD cases, and all AMKL cases, showed mutations/deletions other than GATA1, in genes proven as transformation drivers in non-DS leukemia (EZH2, APC, FLT3, JAK1, PARK2-PACRG, EXT1, DLEC1, and SMC3). One patient at the TMD stage revealed 2 clonal expansions with different GATA1 mutations, of which 1 clone had an additional driver mutation. Interestingly, it was the other clone that gave rise to AMKL after accumulating mutations in 7 other genes. Data suggest that GATA1 mutations alone are sufficient for clonal expansions, and additional driver mutations at the TMD stage do not necessarily predict AMKL progression. Later in infancy, leukemic progression requires “third-hit driver” mutations/somatic copy-number alterations found in non-DS leukemias. Putative driver mutations affecting WNT (wingless-related integration site), JAK-STAT (Janus kinase/signal transducer and activator of transcription), or MAPK/PI3K (mitogen-activated kinase/phosphatidylinositol-3 kinase) pathways were found in all cases, aberrant activation of which converges on overexpression of MYC. Key Points DS TMD shows no DNA rearrangements and a low rate of mutations other than GATA1. DS AMKL always has rearrangements and mutations in genes known for leukemic progression; affected pathways share upregulation of MYC.Keywords
This publication has 52 references indexed in Scilit:
- Tumorigenesis in Down's syndrome: big lessons from a small chromosomeNature Reviews Cancer, 2012
- Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndromeBlood, 2009
- Megakaryocyte hyperproliferation without GATA1 mutation in foetal liver of a case of Down syndrome with hydrops foetalisBritish Journal of Haematology, 2008
- Haematology of Down syndromeArchives of Disease in Childhood - Fetal and Neonatal Edition, 2007
- Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorderThe Lancet, 2003
- Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndromeNature Genetics, 2002
- Incidence and Treatment of Potentially Lethal Diseases in Transient Leukemia of Down Syndrome: Pediatric Oncology Group StudyJournal of Pediatric Hematology/Oncology, 2002
- Risks of leukaemia and solid tumours in individuals with Down's syndromeThe Lancet, 2000
- Leukemia in Down Syndrome: A ReviewPediatric Hematology and Oncology, 1992
- Simultaneous Occurrence of Mongolism and LeukemiaA.M.A. Journal of Diseases of Children, 1957